6533b852fe1ef96bd12aaf72
RESEARCH PRODUCT
COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety
Luxi N.Giovanazzi A.Capuano A.Crisafulli S.Cutroneo P. M.Fantini M. P.Ferrajolo C.Moretti U.Poluzzi E.Raschi E.Ravaldi C.Reno C.Tuccori M.Vannacci A.Zanoni G.Trifiro G.Trifiro G.Petrelli G.Girotti S.Arzenton E.Magro L.Lora R.Bellantuono D.Sabaini A.Firenze A.Zodda D.Guidotti F.Zappone M.Alagna B.Spina E.Minore C.Costantino C.Conforto A.Vitale F.Morreale I.Marsala L.Farinella D.Bavetta S.Sapigni E.Potenza A. M.Podetti D.Nikitina V.Ricciardelli R.Mogheiseh N.Croce S.Paltrinieri B.Castellani S.Sangiorgi E.Selleri M.Lucchesi S.Catucci G.Savini D.Sacripanti C.Faccioli M.Romio M. S.Rossi L.Radici S.Negri G.Fares L.Ajolfi C.Fadda A.Chiarello A.Pieraccini F.Pappalardo F.Bonaiuti R.Lombardi N.Crescioli G.Tessari R.Zandona E.Marchiori F.Chiamulera C.Senna G.Crivellaro M. A.Cancian M.Venturini F.Ferri M.Leonardi L.Orzetti S.Caccin E.Baldo P.Rafaniello C.Pagliaro C.Mercaldo M.Fucile A.Di Giorgio A.Tari M.Manna S.Farina G.Di Mauro C.De Carlo I.Senesi I.Pileggi C.Palleria C.Gallelli L.De Sarro G.Trabace L.Morgese M.Schiavone S.Tucci P.Bove M.Lapi F.Cricelli C.Racagni G.Tonolo S.Leopardi E.Fava G.Giuffrida S.Amato V.Gambera M.Montresor V.subject
AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusinessdescription
To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overview pre- and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in the above-mentioned special cohorts. In addition, we summarise the recommendations of the scientific societies and regulatory agencies about COVID-19 primary prevention in the same vaccinee categories. Supplementary Information The online version contains supplementary material available at 10.1007/s40264-021-01131-6.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-11-05 |